Securities code: 600420 securities abbreviation: Shanghai Shyndec Pharmaceutical Co.Ltd(600420) Announcement No.: 2022-006 bond Code: 110057 bond abbreviation: Modern convertible bond
Shanghai Shyndec Pharmaceutical Co.Ltd(600420)
Announcement of 2021 annual performance express
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. The main financial data of Shanghai Shyndec Pharmaceutical Co.Ltd(600420) (hereinafter referred to as “the company”) in 2021 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data shall be subject to the data disclosed in the company’s 2021 annual report, and investors are reminded of investment risks.
1、 Main financial data and indicators in 2021
Unit: RMB
Increase / decrease range of the project in the same period of last year in the reporting period (%)
Total operating income 13945244439.86 12556281595.67 11.06
Operating profit 884156103.45 1024193796.79 -13.67
Total profit 918469446.58 1041126801.27 -11.78
Net profit attributable to shareholders of listed company 567517104.23 648792627.72 -12.53
Deduction attributable to shareholders of listed companies
Net profit of recurring profit and loss 496615999.97 516310228.88 -3.81
Basic earnings per share (yuan / share) 0.5526 0.6318 -12.53
The weighted average return on net assets (%) decreased by 1.46, 6.79 and 8.25 percentage points
Increase / decrease range (%)
Total assets 19051741904.95 18349337318.43 3.83
Owners attributable to shareholders of listed companies
Equity 8591999917.18 8131208694.81 5.67
Share capital 1026964555.00 1026959376.00 0.00
Net income per share attributable to shareholders of listed companies
Assets (yuan / share) 8.3664 7.9178 5.67
Note 1. The above data are filled in with the data of the company’s consolidated statements; The opening amount of this report is the statement amount after the implementation of the new lease standards. Note 2. Due to the conversion of convertible corporate bonds issued by the company into shares, the share capital increased by 5179 shares during the reporting period.
Securities code: 600420 securities abbreviation: Shanghai Shyndec Pharmaceutical Co.Ltd(600420) Announcement No.: 2022-006 bond Code: 110057 bond abbreviation: Modern convertible bond
2、 Description of operating performance and financial status
In 2021, in the face of repeated epidemic situations outside China and complex and changeable market competition, the company comprehensively promoted normalized epidemic prevention and control and steady operation of enterprises, actively implemented medium and long-term development plans and actively adjusted product structure. The annual operating revenue was 13945.2444 million yuan, an increase of 11.06% over the same period of last year.
During the reporting period, the company realized a net profit attributable to the shareholders of the listed company of 567.5171 million yuan, a decrease of 12.53% over the same period of the previous year; The net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses was 496.616 million yuan, a decrease of 3.81% over the same period of the previous year. The main reason for the year-on-year decrease in the company’s operating profit, total profit and net profit attributable to the shareholders of the listed company in the current period is that according to the preliminary results of the goodwill impairment test of the subsidiary by the evaluation institution and following the principle of prudence, the company plans to withdraw the goodwill impairment provision for the subsidiary Sinopharm Yixin Pharmaceutical Co., Ltd. and Sinopharm Shantou Jinshi Pharmaceutical Co., Ltd, Sinopharm Xinyi plans to withdraw 29.0108 million yuan and Sinopharm Jinshi plans to withdraw 103.1354 million yuan (see announcement on withdrawing goodwill impairment provision No. 2022-007 on the same day for details). The above amount of goodwill impairment provision is the preliminary result calculated by the evaluation institution. In the future, a special evaluation report will be issued on the goodwill test at the end of the reporting period according to the year-end final accounts, and the impairment of goodwill and other assets will be confirmed after the audit by the audit institution. After deducting the impact of the above goodwill impairment, the company realized a net profit attributable to the shareholders of the listed company of 699663200 yuan, an increase of 0.88% over the same period of the previous year. During the reporting period, due to the year-on-year decrease in the recognized non recurring profits and losses, the decline in the net profit after deducting the non recurring profits and losses attributable to the shareholders of the listed company was significantly lower than that attributable to the shareholders of the listed company.
3、 Risk tips
The main financial data of 2021 contained in this announcement are preliminary accounting data and have not been audited by an accounting firm. The main indicators such as net profit attributable to the shareholders of the listed company may be different from the data disclosed in the company’s 2021 annual report. The specific data shall be subject to the data disclosed in the company’s 2021 annual report. Please pay attention to the investment risk.
It is hereby announced.
Shanghai Shyndec Pharmaceutical Co.Ltd(600420) board of directors
January 15, 2022
